NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.
Advanced Solid Tumor|Advanced Cancer|Triple Negative Breast Cancer
DRUG: NBE-002
Recommended Phase 2 Dose (RP2D) (Phase 1), The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data, Up to 48 months|Anti-tumor Activity (Phase 2), Anti-tumor activity will be assessed by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, Up to 60 months
Incidence of Adverse Events (Safety and Tolerability), Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events, Up to 60 months|Preliminary Anti-tumor Activity (Phase 1), Preliminary anti-tumor activity will be assessed by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, Up to 48 months|Concentrations of NBE-002, Pharmacokinetic profile will be characterized by concentrations of NBE-002, Up to 60 months|Concentrations of NBE-002-reactive antibodies, Immunogenicity profile will be characterized by concentrations of NBE-002-reactive antibodies, Up to 60 months
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.